Not yet recruitingInterventionalPhase 1Last updated Aug 7, 2026

PSTC100 Study in Healthy Adult Subjects

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PSTC100 in Healthy Adult Subjects

Overview

ClinicalTrials.gov ID: NCT07752472
Lead Sponsor: Prospect Therapeutics (Nanjing) LimitedINDUSTRY
Brief Summary: This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic (PD) characteristics of PSTC100 in healthy adult subjects.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Sep 7, 2026Estimated
Primary Completion Date: Jul 12, 2027Estimated
Completion Date: Oct 10, 2027Estimated

Study Record Dates

First Submitted: Aug 3, 2026
First Submitted that Met QC Criteria: Aug 3, 2026
First Posted: Aug 7, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 3, 2026
Last Update Posted: Aug 7, 2026Actual
Last Verified: Aug 2026

NCT07702279Not yet recruiting

PSTB100 Study in Healthy Adult Subjects

NCT03468413Unknown status

A First-in-human Phase 1 Study of CP1050

NCT04756531Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

NCT05414734Withdrawn

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects

NCT05070702Completed

First in Human Study of CT-1500 in Healthy Participants

NCT04286750Completed

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239